Front Row Advisors’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36K | Hold |
297
| – | – | 0.01% | 252 |
|
|
2025
Q4 | $31.5K | Hold |
297
| – | – | 0.01% | 257 |
|
|
2025
Q3 | $25.2K | Sell |
297
-81
| -21% | -$6.67K | 0.01% | 284 |
|
|
2025
Q2 | $30.2K | Hold |
378
| – | – | 0.01% | 253 |
|
|
2025
Q1 | $34.2K | Hold |
378
| – | – | 0.01% | 247 |
|
|
2024
Q4 | $37.9K | Buy |
378
+72
| +24% | +$7.42K | 0.01% | 243 |
|
|
2024
Q3 | $35K | Sell |
306
-128
| -29% | -$15.2K | 0.01% | 251 |
|
|
2024
Q2 | $54.1K | Hold |
434
| – | – | 0.02% | 265 |
|
|
2024
Q1 | $57.6K | Buy |
434
+178
| +70% | +$21.9K | 0.02% | 243 |
|
|
2023
Q4 | $28.1K | Sell |
256
-128
| -33% | -$13.3K | 0.01% | 219 |
|
|
2023
Q3 | $39.8K | Buy |
384
+21
| +6% | +$2.26K | 0.02% | 259 |
|
|
2023
Q2 | $42K | Hold |
363
| – | – | 0.02% | 258 |
|
|
2023
Q1 | $39K | Buy |
363
+96
| +36% | +$10.4K | 0.02% | 269 |
|
|
2022
Q4 | $30K | Sell |
267
-38
| -12% | -$3.88K | 0.02% | 299 |
|
|
2022
Q3 | $27K | Sell |
305
-20
| -6% | -$1.78K | 0.01% | 317 |
|
|
2022
Q2 | $30K | Sell |
325
-14
| -4% | -$1.24K | 0.01% | 301 |
|
|
2022
Q1 | $28K | Hold |
339
| – | – | 0.01% | 339 |
|
|
2021
Q4 | $26K | Buy |
339
+160
| +89% | +$12.7K | 0.01% | 371 |
|
|
2021
Q3 | $14K | Hold |
179
| – | – | 0.01% | 492 |
|
|
2021
Q2 | $14K | Sell |
179
-8
| -4% | -$595 | 0.01% | 495 |
|
|
2021
Q1 | $14K | Hold |
187
| – | – | 0.01% | 481 |
|
|
2020
Q4 | $15K | Hold |
187
| – | – | 0.01% | 435 |
|
|
2020
Q3 | $14K | Sell |
187
-73
| -28% | -$5.72K | 0.01% | 444 |
|
|
2020
Q2 | $19K | Sell |
260
-24
| -8% | -$1.81K | 0.01% | 353 |
|
|
2020
Q1 | $22K | Buy |
284
+1
| +0.4% | +$79 | 0.01% | 320 |
|
|
2019
Q4 | $25K | Sell |
283
-19
| -6% | -$1.56K | 0.02% | 293 |
|
|
2019
Q3 | $24K | Hold |
302
| – | – | 0.02% | 290 |
|
|
2019
Q2 | $24K | Sell |
302
-29
| -9% | -$2.22K | 0.02% | 289 |
|
|
2019
Q1 | $26K | Buy |
331
+74
| +29% | +$5.54K | 0.02% | 275 |
|
|
2018
Q4 | $19K | Sell |
257
-243
| -49% | -$17.2K | 0.02% | 299 |
|
|
2018
Q3 | $34 | Buy |
500
+83
| +20% | +$5.29K | 0.02% | 241 |
|
|
2018
Q2 | $25 | Hold |
417
| – | – | 0.02% | 306 |
|
|
2018
Q1 | $22K | Buy |
417
+101
| +32% | +$5.46K | 0.02% | 321 |
|
|
2017
Q4 | $17K | Buy |
+316
| New | +$17.5K | 0.01% | 356 |
|
Other funds holding MRK
VCM
VPM
Front Row Advisors's MRK Position: Q1 2026 in Review
Front Row Advisors held its Merck (MRK) position steady in Q1 2026 at 297 shares worth $36K. The position accounts for 0.01% of the portfolio, ranked #252.
Front Row Advisors first reported a position in MRK in Q4 2017 and has held it in 34 quarters since. The position peaked at $57.6K in Q1 2024. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Front Row Advisors held 297 shares of Merck worth $36K as of Q1 2026.
- Front Row Advisors left its Merck share count unchanged in Q1 2026.
- Merck made up 0.01% of Front Row Advisors's portfolio in Q1 2026, its #252 holding.
- Front Row Advisors first reported a position in Merck in Q4 2017 and has held it in 34 quarters since.
- Front Row Advisors's Merck position peaked at $57.6K in Q1 2024.
- 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.